MedTrace Logo

Palifosfamide in Treating Patients With Recurrent Germ Cell Tumors

NCT01808534 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2015-07-02

Study results available
· View outcomes & findings →

Summary

This phase II trial studies how well palifosfamide works in treating patients with recurrent germ cell tumors. Drugs used in chemotherapy, such as palifosfamide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing

Conditions

  • Adult Central Nervous System Germ Cell Tumor
  • Adult Teratoma
  • Malignant Extragonadal Germ Cell Tumor
  • Malignant Extragonadal Non-Seminomatous Germ Cell Tumor
  • Extragonadal Seminoma
  • Recurrent Malignant Testicular Germ Cell Tumor
  • Recurrent Ovarian Germ Cell Tumor
  • Stage IV Extragonadal Non-Seminomatous Germ Cell Tumor
  • Stage IV Extragonadal Seminoma
  • Stage IV Ovarian Germ Cell Tumor

Interventions

DRUG

palifosfamide

Given IV

Sponsors & Collaborators

  • Alaunos Therapeutics

    collaborator INDUSTRY

  • Indiana University School of Medicine

    lead OTHER

Principal Investigators

  • Lawrence H Einhorn, MD · Indiana University School of Medicine

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-02-28
Primary Completion
2014-11-30
Completion
2014-11-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01808534 on ClinicalTrials.gov